Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris
A Pilot Study to Assess Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris
In the register
The register attaches this trial to Delgocitinib (LEO 124249) (LEO Pharma), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 2
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Participants (registry)
- 30
- Start
- May 2026
- Primary completion
- April 2027 (planned)
- Study completion
- December 2027 (planned)
- Last registry update
- July 2026
- Countries
- United States
Conditions studied: Central Centrifugal Cicatricial Alopecia, Lichen Planopilaris
Interventions: Delgocitinib
Other trials of Delgocitinib (LEO 124249)
Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA)
A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.
LEO 124249 Ointment in the Treatment of Alopecia Areata
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.